on INNATE PHARMA (EPA:IPH)
Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum
Innate Pharma announced its participation in the upcoming Stifel Virtual Targeted Oncology Forum on April 8-9, 2025. The company's executive team will conduct a fireside chat on April 9, from 12:30 to 12:55 p.m. ET. A live webcast and replay will be accessible via Innate Pharma's website, under the Investors section.
The forum will facilitate one-on-one meetings, allowing Innate Pharma to discuss its advanced oncology immunotherapies. As a clinical-stage biotechnology firm, Innate focuses on harnessing the innate immune system with its ANKET® platform, Antibody Drug Conjugates, and monoclonal antibodies.
Listed on Euronext Paris and Nasdaq, Innate Pharma is actively collaborating with major biopharmaceutical companies to foster innovation for cancer treatment.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news